Jon Freels, MD
Pulmonary Disease · Columbia, TNNPI 1336200385
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,145 of the $34,971 with a category attached, or 80.5%. Medtronic accounts for 92.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $13,961 and has fallen 53.7% since, to $6,457 in 2025. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $304.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$32K
- Noah Medical Corporation$915
- Pulmonx Corporation$420
- Covidien LP$273
- Sanofi$153
- Davol Inc.$149
- plus $695 from 17 others
What the payments were for
- Consulting fees$2251%
- Speaking & faculty fees$28,14580%
- Travel & lodging$2,9118%
- Food & beverage$3,49210%
- Education$1971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 62 | $32,365 |
| Noah Medical Corporation | 3 | $915 |
| Pulmonx Corporation | 6 | $420 |
| Covidien LP | 8 | $273 |
| Sanofi | 6 | $153 |
| Davol Inc. | 1 | $149 |
| Insmed, Inc. | 7 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 4 | $74 |
| Intuitive Surgical | 1 | $64 |
| ERBE USA Inc | 1 | $50 |
| AstraZeneca | 2 | $46 |
| Philips North America LLC | 2 | $45 |
| GSK | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $23 |
| Baxter Healthcare | 1 | $20 |
| Novartis | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| AbbVie | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,971 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 212 | $187,497 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $112,361 |
| Breo ElliptaFluticasone/Vilanterol | 114 | $56,180 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $51,361 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $25,691 |
| Spiriva RespimatTiotropium Bromide | 31 | $22,212 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $10,048 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $9,622 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $9,496 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $7,140 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 251 | $7,004 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $7,000 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $6,548 |
| Ventolin HfaAlbuterol Sulfate | 23 | $3,054 |
| Roflumilast | 31 | $2,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $35 | $281,696397 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $46 | $58,501104 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $23 | $41,33057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Columbia
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
- John SwisherKnoxville$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.